EUVIMEDEUVIMED entdecken
Open Access

Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile , United States, 2012–17

Amy S Gargis iD, Maria Karlsson iD, Ashley L Paulick iD, Karen F Anderson, Michelle Adamczyk, Nicholas Vlachos, Alyssa G Kent iD, Gillian McAllister, Susannah L McKay, Alison L Halpin iD, Valerie Albrecht, Davina Campbell und 7 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Amy S Gargis und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antimicrobial susceptibility testing (AST) is not routinely performed for Clostridioides difficile and data evaluating minimum inhibitory concentrations (MICs) are limited. We performed AST and whole genome sequencing (WGS) for 593 C. difficile isolates collected between 2012 and 2017 through the Centers for Disease Control and Prevention's Emerging Infections Program.

Methods

MICs to 6 antimicrobial agents (ceftriaxone, clindamycin, meropenem, metronidazole, moxifloxacin, and vancomycin) were determined using the reference agar dilution method according to Clinical and Laboratory Standards Institute guidelines. Whole genome sequencing was performed on all isolates to detect the presence of genes or mutations previously associated with resistance.

Results

Among all isolates, 98.5% displayed a vancomycin MIC ≤2 μg/mL and 97.3% displayed a metronidazole MIC ≤2 μg/mL. Ribotype 027 (RT027) isolates displayed higher vancomycin MICs (MIC50: 2 μg/mL; MIC90: 2 μg/mL) than non-RT027 isolates (MIC50: 0.5 μg/mL; MIC90: 1 μg/mL) (P < .01). No vanA/B genes were detected. RT027 isolates also showed higher MICs to clindamycin and moxifloxacin and were more likely to harbor associated resistance genes or mutations.

Conclusions

Elevated MICs to antibiotics used for treatment of C. difficile infection were rare, and there was no increase in MICs over time. The lack of vanA/B genes or mutations consistently associated with elevated vancomycin MICs suggests there are multifactorial mechanisms of resistance. Ongoing surveillance of C. difficile using reference AST and WGS to monitor MIC trends and the presence of antibiotic resistance mechanisms is essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsHumansUnited StatesVancomycinMetronidazoleClindamycinMoxifloxacinClostridioidesAnti-Bacterial AgentsGenomicsMicrobial Sensitivity TestsRibotyping

Stichwörter der Autor:innen

Clostridioides difficileagar dilutionantibiotic resistancemetronidazolevancomycin

Substanzen

VancomycinMetronidazoleClindamycinMoxifloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Goldbelt C6, LLC, Chesapeake, Virginia, USA.

ORCID-Profile: Amy S Gargis, Maria Karlsson, Ashley L Paulick, Alyssa G Kent, Alison L Halpin, Christopher A Elkins, L Clifford McDonald, Joseph D Lutgring

Förderung

  • Intramural CDC HHS

Zitieren

APA

Gargis, A. S., Karlsson, M., Paulick, A. L., Anderson, K. F., Adamczyk, M., Vlachos, N., Kent, A. G., McAllister, G., McKay, S. L., Halpin, A. L., Albrecht, V., Campbell, D., Korhonen, L. C., Elkins, C. A., Rasheed, J. K., Guh, A. Y., McDonald, L. C., Lutgring, J. D., & Emerging Infections Program C. difficile Infection Working Group (2023). Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile , United States, 2012–17. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac817

Vancouver

Gargis AS, Karlsson M, Paulick AL, Anderson KF, Adamczyk M, Vlachos N, et al. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile , United States, 2012–17. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac817

BibTeX
@article{Gargis2023,
  author = {Gargis, Amy S and Karlsson, Maria and Paulick, Ashley L and Anderson, Karen F and Adamczyk, Michelle and Vlachos, Nicholas and Kent, Alyssa G and McAllister, Gillian and McKay, Susannah L and Halpin, Alison L and Albrecht, Valerie and Campbell, Davina and Korhonen, Lauren C and Elkins, Christopher A and Rasheed, J Kamile and Guh, Alice Y and McDonald, L Clifford and Lutgring, Joseph D and Emerging Infections Program C. difficile Infection Working Group, Emerging Infections Program C. difficile Infection Working Group},
  title = {Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile , United States, 2012–17},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac817}
}
Kostenlos starten →